Ritam Bandopadhyay

Mr. Ritam Bandopadhyay

student- Master of pharmacy
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2021 in Metabolic Brain Disease
Verified
Journal Article
Closed access
PDF file
AMAwanish Mishra
Awanish Mishra
Ritam BandopadhyayRitam Bandopadhyay
Ritam Bandopadhyay
PSPrabhakar Kumar Singh
Prabhakar Kumar Singh
PMPragya Shakti Mishra
Pragya Shakti Mishra
NSNeha Sharma
Neha Sharma
NKNavneet Khurana
Navneet Khurana

26 October 2021 in Molecules
Verified
Journal Article
Open access
PDF file
AMAwanish Mishra
Awanish Mishra
PMPragya Shakti Mishra
Pragya Shakti Mishra
Ritam BandopadhyayRitam Bandopadhyay
Ritam Bandopadhyay
NKNavneet Khurana
Navneet Khurana
Efthalia AngelopoulouEfthalia Angelopoulou
Efthalia Angelopoulou
Christina PiperiChristina Piperi
Christina Piperi
Chrysin, a herbal bioactive molecule, exerts a plethora of pharmacological effects, including anti-oxidant, anti-inflammatory, neuroprotective, and anti-cancer. A growing body of evidence has highlighted the emerging role of chrysin in a variety of neurological disorders, including Alzheimer’s and Parkinson’s disease, epilepsy, multiple sclerosis, ischemic stroke, traumatic brain injury, and brain tumors. Based on the results of recent pre-clinical studies and evidence from studies in humans, this review is focused on the molecular mechanisms underlying the neuroprotective effects of chrysin in different neurological diseases. In addition, the potential challenges, and opportunities of chrysin’s inclusion in the neurotherapeutics repertoire are critically discussed.

7 April 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
Ritam BandopadhyayRitam Bandopadhyay
Ritam Bandopadhyay
NMNainshi Mishra
Nainshi Mishra
RRRuhi Rana
Ruhi Rana
GKGagandeep Kaur
Gagandeep Kaur
MGMohammed M. Ghoneim
Mohammed M. Ghoneim
AMAwanish Mishra
Awanish Mishra
Parkinson’s disease (PD) is the second leading neurodegenerative disease that is characterized by severe locomotor abnormalities. Levodopa (L-DOPA) treatment has been considered a mainstay for the management of PD; however, its prolonged treatment is often associated with abnormal involuntary movements and results in L-DOPA-induced dyskinesia (LID). Although LID is encountered after chronic administration of L-DOPA, the appearance of dyskinesia after weeks or months of the L-DOPA treatment has complicated our understanding of its pathogenesis. Pathophysiology of LID is mainly associated with alteration of direct and indirect pathways of the cortico-basal ganglia-thalamic loop, which regulates normal fine motor movements. Hypersensitivity of dopamine receptors has been involved in the development of LID; moreover, these symptoms are worsened by concurrent non-dopaminergic innervations including glutamatergic, serotonergic, and peptidergic neurotransmission. The present study is focused on discussing the recent updates in molecular mechanisms and therapeutic approaches for the effective management of LID in PD patients.

25 October 2021 in Biology
Verified
Journal Article
Open access
PDF file
Ritam BandopadhyayRitam Bandopadhyay
Ritam Bandopadhyay
TSTanveer Singh
Tanveer Singh
MGMohammed M. Ghoneim
Mohammed M. Ghoneim
SASultan Alshehri
Sultan Alshehri
Efthalia AngelopoulouEfthalia Angelopoulou
Efthalia Angelopoulou
AMAwanish Mishra
Awanish Mishra
Epilepsy is one of the most common neurological disorders, characterized by recurrent seizures, resulting from abnormally synchronized episodic neuronal discharges. Around 70 million people worldwide are suffering from epilepsy. The available antiepileptic medications are capable of controlling seizures in around 60–70% of patients, while the rest remain refractory. Poor seizure control is often associated with neuro-psychiatric comorbidities, mainly including memory impairment, depression, psychosis, neurodegeneration, motor impairment, neuroendocrine dysfunction, etc., resulting in poor prognosis. Effective treatment relies on early and correct detection of epileptic foci. Although there are currently a few well-established diagnostic techniques for epilepsy, they lack accuracy and cannot be applied to patients who are unsupportive or harbor metallic implants. Since a single test result from one of these techniques does not provide complete information about the epileptic foci, it is necessary to develop novel diagnostic tools. Herein, we provide a comprehensive overview of the current diagnostic tools of epilepsy, including electroencephalography (EEG) as well as structural and functional neuroimaging. We further discuss recent trends and advances in the diagnosis of epilepsy that will enable more effective diagnosis and clinical management of patients.

20 February 2023 in Metabolic Brain Disease
Verified
Journal Article
Closed access
PDF file
MKMohammad Ahmed Khan
Mohammad Ahmed Khan
NHNafis Haider
Nafis Haider
TSTanveer Singh
Tanveer Singh
Ritam BandopadhyayRitam Bandopadhyay
Ritam Bandopadhyay
MGMohammed M. Ghoneim
Mohammed M. Ghoneim
AMAwanish Mishra
Awanish Mishra

1 November 2022 in Bioengineering
Verified
Journal Article
Open access
PDF file
Javed AhmadJaved Ahmad
Javed Ahmad
HAHassan A. Albarqi
Hassan A. Albarqi
Mohammad Zaki AhmadMohammad Zaki Ahmad
Mohammad Zaki Ahmad
MOMohamed A. A. Orabi
Mohamed A. A. Orabi
Shadab MDShadab MD
Shadab MD
AMAwanish Mishra
Awanish Mishra
Osteoporosis, a chronic bone disorder, is one of the leading causes of fracture and morbidity risk. Numerous medicinally important herbs have been evaluated for their efficacy in improving bone mass density in exhaustive preclinical and limited clinical studies. Nigella sativa L. has been used as local folk medicine, and traditional healers have used it to manage various ailments. Its reported beneficial effects include controlling bone and joint diseases. The present manuscript aimed to provide a sound discussion on the pharmacological evidence of N. sativa and its active constituent, thymoquinone, for its utility in the effective management of osteoporosis. N. sativa is reported to possess anti-IL-1 and anti-TNF-α-mediated anti-inflammatory effects, leading to positive effects on bone turnover markers, such as alkaline phosphatase and tartrate-resistant acid phosphatase. It is reported to stimulate bone regeneration by prompting osteoblast proliferation, ossification, and decreasing osteoclast cells. Thymoquinone from N. sativa has exhibited an antioxidant effect on bone tissue by reducing the FeNTA-induced oxidative stress. The present manuscript highlights phytochemistry, pharmacological effect, and the important mechanistic perspective of N. sativa and its active constituents for the management of osteoporosis. Further, it also provides sound discussion on the utilization of a nanotechnology-mediated drug delivery approach as a promising strategy to improve the therapeutic performance of N. sativa and its active constituent, thymoquinone, in the effective management of osteoporosis.